BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor prognosis associated with high-grade gliomas, BRAF mutations in glioma are of considerable interest. In this review, we present the spectrum o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreck, Karisa C., Grossman, Stuart A., Pratilas, Christine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769482/
https://www.ncbi.nlm.nih.gov/pubmed/31466300
http://dx.doi.org/10.3390/cancers11091262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769482/
https://www.ncbi.nlm.nih.gov/pubmed/31466300
http://dx.doi.org/10.3390/cancers11091262

Ejemplares similares